Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Cannabidiol
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
ANANDA Tests Nantheia™ ATL5 for Opioid Use Disorder and Chronic Pain
Details : Nantheia ATL5, an investigational drug using cannabidiol (CBD), leveraging ANANDA’s proprietary delivery technology, for its potential efficacy in treating co-occurring OUD and chronic pain.
Brand Name : Nantheia Atl5
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 15, 2024
Lead Product(s) : Cannabidiol
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Cannabidiol
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Nantheia ATL5 creates new potential for cannabidiol therapeutics, having the ability to reduce opioid intake for individuals being treated for OUD and facilitating voluntary opioid sparing.
Brand Name : Nantheia ATL5
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 28, 2023
Lead Product(s) : Cannabidiol
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Cannabidiol
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Recipient : University of Nebraska Medical Center
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Nantheia ATL5 creates new potential for cannabidiol therapeutics, having the ability to reduce opioid intake for individuals being treated for OUD and facilitating voluntary opioid sparing.
Brand Name : Nantheia ATL5
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 14, 2023
Lead Product(s) : Cannabidiol
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Recipient : University of Nebraska Medical Center
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Cannabidiol
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : NYU Langone Health
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Nantheia ATL5, an oral therapy containing 100mg of cannabidiol per capsule, features proprietary delivery technology (Liquid Structure) touted as enhancing the effectiveness and stability of cannabidiol.
Brand Name : Nantheia
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 30, 2022
Lead Product(s) : Cannabidiol
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : NYU Langone Health
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Cannabidiol
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Pre-clinical and initial clinical studies show that ANANDA's Liquid Structure™ delivery technology enhances the effectiveness and stability of cannabidiol. Nantheia™ ATL5 (cannabidiol) is an oral product with 100mg cannabidiol per softgel capsule.
Brand Name : Nantheia ATL5
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 26, 2022
Lead Product(s) : Cannabidiol
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Cannabidiol
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : University of Nebraska Medical Center
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Nantheia ATL5 is an investigational drug that uses cannabidiol in ANANDA’s propriety Liquid Structure delivery technology. Pre-clinical and initial clinical studies show that ANANDA’s Liquid Structure™ delivery technology.
Brand Name : Nantheia
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 17, 2022
Lead Product(s) : Cannabidiol
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : University of Nebraska Medical Center
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Cannabidiol
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I/ Phase II
Sponsor : NYU Grossman School of Medicine
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Nantheia™ A1002N5S is an investigational drug that uses CBD in ANANDA’s propriety Liquid Structure delivery technology. Pre-clinical and initial clinical studies show that ANANDA’s Liquid Structure™ delivery technology enhances the effectiveness ...
Brand Name : Nantheia
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 08, 2022
Lead Product(s) : Cannabidiol
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I/ Phase II
Sponsor : NYU Grossman School of Medicine
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Cannabidiol
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Lyotropic Delivery Systems
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Nantheia™ ATL5, an investigational drug using cannabidiol in ANANDA’s proprietary Liquid Structure™ delivery technology for opioid use disorder. Nantheia™ ATL5 is an oral softgel capsule and is investigational drug utilizing Liquid Structure™ t...
Brand Name : Nantheia
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 19, 2021
Lead Product(s) : Cannabidiol
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Lyotropic Delivery Systems
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?